Again, a significant decrease in MAPT levels was observed in the two X55-sensitive CDA-proficient tumor cells, but not in X55-resistant CDA-proficient tumor cells (Fig. 4c and d and Supplementary Fig. 5c and d). This evidence concerns the gene CDA and neoplasm.